Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancerNew analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth

Frontiers in Medicine Published May 12, 2026 Study authors: Tianfu Dai, Yu Chen, Xuelian Dai, Yixin Chen, Xiaobo Pan, Jingqi Chen, Xingchen Liu DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider dual ICI therapy for advanced NSCLC; survival benefit observed but safety data not reported.

This meta-analysis examines the efficacy of dual immune checkpoint inhibitor therapy, combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors, compared to control treatments. The analysis included data from 6,369 patients with advanced or metastatic non-small cell lung cancer. The primary outcome assessed was overall survival, with progression-free survival as a secondary outcome. Follow-up duration was not reported for the pooled results.

The results indicated significantly better overall survival in the dual treatment group, with a hazard ratio of 0.84 and a 95% confidence interval of 0.76 to 0.92. The p-value for this finding was 0.003. Progression-free survival also showed significant benefit, with a hazard ratio of 0.78 and a 95% confidence interval of 0.68 to 0.89. The p-value for progression-free survival was 0.002.

The authors state that the efficacy difference varies across subgroups. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in this source. Funding or conflicts of interest were not reported. The practice relevance is that dual therapy improves prognosis in this population, though clinicians should consider the lack of reported safety information when interpreting these findings.

A major review looked at data from over 6,300 patients with advanced or metastatic non-small cell lung cancer. These patients received either a combination of two immune checkpoint drugs or standard control treatments. The study aimed to see if using both drugs at once would help patients live longer and manage their disease better.

Patients who got the dual drug treatment lived significantly longer than those on control treatments. The data showed a clear benefit for the group receiving both types of immune therapy. This combination approach also helped stop the cancer from spreading or getting worse for a longer time compared to other options.

Doctors noted that the benefits of this dual treatment varied depending on specific patient subgroups. While the study did not report detailed safety data in this summary, the overall results suggest this method improves the outlook for people with this serious form of lung cancer.

What this means for you:

Combining two immune drugs helps patients with advanced lung cancer live longer and delays cancer growth compared to standard treatments.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Dual immune checkpoint inhibitor (ICI) therapy (PD-1/PD-L1+CTLA-4 inhibitors) has emerged as a promising strategy, but its efficacy and optimal patient selection remain uncertain. This meta-analysis aimed to evaluate the efficacy of dual ICI therapy in advanced/metastatic non-small cell lung cancer (NSCLC) based on randomized controlled trials (RCTs). We systematically searched Cochrane Library, Embase, Web of Science, and PubMed from inception to August 2025 for RCTs comparing dual ICI therapy (PD-1/PD-L1+CTLA-4 inhibitors) versus control treatments in advanced/metastatic NSCLC. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Ten RCTs comprising 6,369 patients were included. The OS (HR = 0.84, 95%CI 0.76-0.92, p=0.003) and PFS (HR = 0.78, 95%CI 0.68-0.89, p=0.002) of patients who received dual ICI treatment were significantly better than those in the control group. Subgroup analyses of the OS revealed significant benefits, including: squamous, non-squamous, PD-1 inhibitor, PD-L1 inhibitor, bone metastases, without bone metastases, male, age Dual ICI therapy with PD-1/PD-L1 plus CTLA-4 inhibitors improves prognosis in advanced/metastatic NSCLC, with efficacy difference across subgroups. TMB may serve as a complementary predictive biomarker for dual immunotherapy.

Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancerNew analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancerNew analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth

More on Non-Small Cell Lung Cancer

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties